Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Info Diabetologie
Erschienen in: Info Diabetologie 4/2017

04.09.2017 | Typ-2-Diabetes | zertifizierte fortbildung

Bariatrische Chirurgie bei Typ-2-Diabetes

Der Magenbypass — eine Chance auf Diabetesremission mit Haken und Ösen

verfasst von: Dr. Gabi Franke-Ullmann, Dr. Marie-Christine Simon

Erschienen in: Info Diabetologie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bariatrische Chirurgie, insbesondere die Magenbypasschirurgie nach Roux, ist eine effektive Methode zum dauerhaften Gewichtsverlust mit der Chance auf langfristige Diabetesremission. Mit konservativen Maßnahmen ist ein derartiger Effekt bei massiv ädipösen Patienten nur äußerst selten zu erreichen. Allerdings darf man nicht vergessen, dass ein solcher Eingriff auch neue Herausforderungen mit sich bringt.
Literatur
1.
Dumon, K.R. and K.M. Murayama, Bariatric surgery outcomes. Surg Clin North Am, 2011. 91(6): p. 1313–38, x.CrossRefPubMed
2.
World Health Organization, W., Global Health Observatory (GHO) data: Overweight and obesity Adults aged 18+. 2017.
3.
World Health Organization, W., Media centre Obesity and overweight: Fact sheet. 2016.
4.
World Health Organization, W., Global Report on Diabetes. 2016, World Health Organization.
5.
Weiner, R.A., Adipositas und Adipositaschirurgie 2016- wo stehen wir?. Chirurgische Allgemeinzeitung, 2016. 17(11+12): p. 4.
6.
Klein S.K.S., Behrendt S, Pulst A, Bleß H-H., Weißbuch Adipositas. Versorgungssituation in Deutschland.. MWV Medizinisch Wissenschaftliche Verlagsgesellschaft mbH und CoKG. Berlin 2016.
7.
8.
Meyer, G.S., M. S.; Hohmann, C.;, Bariatrische Chirurgie zwischen Evidenz und fehlender Akzeptanz. Chirurgische Allgemeinzeitung, 2016.
9.
Must, A., et al., The disease burden associated with overweight and obesity. Jama, 1999. 282(16): p. 1523–9.CrossRefPubMed
10.
Shaw, J.E., R.A. Sicree, and P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract, 2010. 87(1): p. 4–14.CrossRefPubMed
11.
Federation, I.D. IDF Diabetes Atlas, 6th edn.. Diabetes Atlas 2013 2013 [cited 2014 01.04.2015]; 6th edn. Brussels, Belgium: International Diabetes Federation, 2013:[International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://​www.​idf.​org/​diabetesatlas].
12.
Muoio, D.M. and C.B. Newgard, Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol, 2008. 9(3): p. 193–205.CrossRefPubMed
13.
Nationalen Versorgungs Leitlinie (NVL): Therapie des Typ-2-Diabetes. AWMF-Register:Nr.: nvl-001g, 2016.
14.
Stark Casagrande, S., et al., The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care, 2013. 36(8): p. 2271–9.CrossRefPubMedPubMedCentral
15.
Williamson, D.F., et al., Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care, 2000. 23(10): p. 1499–504.CrossRefPubMed
16.
Ribaric, G., J.N. Buchwald, and T.W. McGlennon, Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg, 2014. 24(3): p. 437–55.CrossRefPubMed
17.
Christiansen, T., et al., Weight loss maintenance in severely obese adults after an intensive lifestyle intervention: 2- to 4-year follow-up. Obesity (Silver Spring), 2007. 15(2): p. 413–20.CrossRef
18.
19.
Pories, W.J., et al., Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg, 1995. 222(3): p. 339–50; discussion 350-2.CrossRefPubMedPubMedCentral
20.
21.
National Institutes of Health, N., NIH Consensus Statement 1991. Gastrointestinal Surgery for Severe Obesity. National Institutes of Health Consensus Development Conference Statement. 1991. 9(1): p. 20.
22.
Rubino, F., et al., Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med, 2010. 61: p. 393–411.CrossRefPubMed
23.
Thomas, S. and P. Schauer, Bariatric surgery and the gut hormone response. Nutr Clin Pract, 2010. 25(2): p. 175–82.CrossRefPubMed
24.
Brethauer, S.A., et al., Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg, 2013. 258(4): p. 628–36; discussion 636-7.PubMedPubMedCentral
25.
Sjostrom, L., et al., Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med, 2004. 351(26): p. 2683–93.CrossRefPubMed
26.
Weiner, R.A., Geschichte der Adipositaschirurgie in Deutschland-ein Rückblick Chirurgische Allgemeinzeitung, 2016. 17(11+12): p. 5.
27.
Nannipieri, M., et al., Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab, 2013. 98(11): p. 4391–9.CrossRefPubMed
28.
Foo, J., et al., Studies in insulin resistance following very low calorie diet and/or gastric bypass surgery. Obes Surg, 2011. 21(12): p. 1914–20.CrossRefPubMed
29.
Peterli, R., et al., Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg, 2012. 22(5): p. 740–8.CrossRefPubMedPubMedCentral
30.
Campioni, M., et al., Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab, 2007. 292(1): p. E54–60.CrossRefPubMed
31.
Lips, M.A., et al., Calorie restriction is a major determinant of the short-term metabolic effects of gastric bypass surgery in obese type 2 diabetic patients. Clin Endocrinol (Oxf), 2014. 80(6): p. 834–42.CrossRef
32.
Theodorakis, M.J., et al., Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab, 2006. 290(3): p. E550–9.CrossRefPubMed
33.
34.
Meier, J.J. and M.A. Nauck, Incretins and the development of type 2 diabetes. Curr Diab Rep, 2006. 6(3): p. 194–201.CrossRefPubMed
35.
36.
Laferrere, B., et al., Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab, 2008. 93(7): p. 2479–85.CrossRefPubMedPubMedCentral
37.
Berggren, J., et al., Roux-en-Y gastric bypass versus calorie restriction: support for surgery per se as the direct contributor to altered responses of insulin and incretins to a mixed meal. Surg Obes Relat Dis, 2017. 13(2): p. 234–242.CrossRefPubMed
38.
Svendsen, P.F., et al., The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scand J Clin Lab Invest, 2012. 72(5): p. 410–9.CrossRefPubMed
39.
Morinigo, R., et al., Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab, 2006. 91(5): p. 1735–40.CrossRefPubMed
40.
Rhee, N.A., et al., Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia, 2015. 58(10): p. 2254–8.CrossRefPubMed
41.
Mingrone, G. and L. Castagneto-Gissey, Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab, 2009. 35(6 Pt 2): p. 518–23.CrossRefPubMed
42.
Jackness, C., et al., Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and beta-cell Function in type 2 diabetic patients. Diabetes, 2013. 62(9): p. 3027–32.CrossRefPubMedPubMedCentral
43.
Jazet, I.M., et al., Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin. Metabolism, 2005. 54(6): p. 705–12.CrossRefPubMed
44.
Knop, F.K. and R. Taylor, Mechanism of metabolic advantages after bariatric surgery: it’s all gastrointestinal factors versus it’s all food restriction. Diabetes Care, 2013. 36 Suppl 2: p. S287–91.CrossRefPubMedPubMedCentral
45.
Kashyap, S.R., et al., Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond), 2010. 34(3): p. 462–71.CrossRef
46.
Pournaras, D.J., et al., Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg, 2010. 252(6): p. 966–71.CrossRefPubMed
47.
Campos, G.M., et al., Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg, 2010. 14(1): p. 15–23.CrossRefPubMed
48.
Bojsen-Moller, K.N., et al., Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes, 2014. 63(5): p. 1725–37.CrossRefPubMed
49.
Lim, E.L., et al., Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia, 2011. 54(10): p. 2506–14.CrossRefPubMedPubMedCentral
50.
Schwarz, A., et al., Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg, 1996. 20(1): p. 60–6; discussion 66-7.CrossRefPubMed
51.
Samson, S.L. and A.J. Garber, Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. Best Pract Res Clin Endocrinol Metab, 2016. 30(3): p. 357–71.CrossRefPubMed
52.
Wickremesekera, K., et al., Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg, 2005. 15(4): p. 474–81.CrossRefPubMed
53.
Ponce, J., et al., Effect of Lap-Band-induced weight loss on type 2 diabetes mellitus and hypertension. Obes Surg, 2004. 14(10): p. 1335–42.CrossRefPubMed
54.
Rubino, F. and J. Marescaux, Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg, 2004. 239(1): p. 1–11.CrossRefPubMedPubMedCentral
55.
Cohen, R.V., et al., Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. Surg Obes Relat Dis, 2007. 3(2): p. 195–7.CrossRefPubMed
56.
Cohen, R., et al., Role of proximal gut exclusion from food on glucose homeostasis in patients with Type 2 diabetes. Diabet Med, 2013. 30(12): p. 1482–6.CrossRefPubMed
57.
Schouten, R., et al., A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg, 2010. 251(2): p. 236–43.CrossRefPubMed
58.
Dogan, K., et al., Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes Surg, 2014. 24(11): p. 1835–42.CrossRefPubMed
59.
Laurino Neto, R.M., et al., Comorbidities remission after Roux-en-Y Gastric Bypass for morbid obesity is sustained in a long-term follow-up and correlates with weight regain. Obes Surg, 2012. 22(10): p. 1580–5.CrossRefPubMed
60.
61.
Cohen, R.V., et al., Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care, 2012. 35(7): p. 1420–8.CrossRefPubMedPubMedCentral
62.
Schauer, P.R., et al., Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg, 2003. 238(4): p. 467–84; discussion 84-5.PubMedPubMedCentral
63.
Chikunguwo, S.M., et al., Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis, 2010. 6(3): p. 254–9.CrossRefPubMed
64.
Jimenez, A., et al., Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg, 2012. 256(6): p. 1023–9.CrossRefPubMed
65.
Arterburn, D.E., et al., A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg, 2013. 23(1): p. 93–102.CrossRefPubMedPubMedCentral
66.
Hall, T.C., et al., Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg, 2010. 20(9): p. 1245–50.CrossRefPubMed
67.
Rehfeld, J.F., A centenary of gastrointestinal endocrinology. Horm Metab Res, 2004. 36(11-12): p. 735–41.CrossRefPubMed
68.
Vrieze, A., et al., Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 2012. 143(4): p. 913–6 e7.CrossRefPubMed
69.
Aron-Wisnewsky, J. and K. Clement, The effects of gastrointestinal surgery on gut microbiota: potential contribution to improved insulin sensitivity. Curr Atheroscler Rep, 2014. 16(11): p. 454.CrossRefPubMed
70.
Schauer, P.R., et al., Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med, 2012. 366(17): p. 1567–76.CrossRefPubMedPubMedCentral
71.
Courcoulas, A.P., et al., Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. JAMA Surg, 2015. 150(10): p. 931–40.CrossRefPubMedPubMedCentral
72.
Norris, S.L., et al., Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med, 2004. 117(10): p. 762–74.CrossRefPubMed
73.
Sjostrom, L., et al., Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med, 2007. 357(8): p. 741–52.CrossRefPubMed
74.
Augurzky B, F.K., Pilny A, Wübker A. Bohm S, Lehmann B, Priess H-W, Reinacher U., BARMER GEK Report Krankenhaus 2016 Schwerpunkt: Adipositas. BARMER GEK, Verlag Asgard Verlagsservice GmbH, Siegburg 2016: p. 236.
75.
Rubino, F., et al., The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg, 2010. 251(3): p. 399–405.CrossRefPubMed
76.
Rubino, F., et al., Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 2016. 39(6): p. 861–77.CrossRefPubMed
77.
Olbers, T., et al., Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. Lancet Diabetes Endocrinol, 2017. 5(3): p. 174–183.CrossRefPubMed
78.
Inge, T.H., et al., Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. Lancet Diabetes Endocrinol, 2017. 5(3): p. 165–173.CrossRefPubMed
79.
Nergaard, B.J., et al., Gastric bypass with long alimentary limb or long pancreato-biliary limb—long-term results on weight loss, resolution of co-morbidities and metabolic parameters. Obes Surg, 2014. 24(10): p. 1595–602.CrossRefPubMedPubMedCentral
80.
le Roux, C.W., et al., Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg, 2007. 246(5): p. 780–5.CrossRefPubMed
81.
Stein, J., et al., Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther, 2014. 40(6): p. 582–609.CrossRefPubMed
82.
Prager, G., Hypoglykämien nach Adipositaschirurgie- Inzidenz, Pathophysiologie und Klinik. 32nd Annual Conference of the German Association for the Study of Obesity (DAG) e.V., 2016(Vortrag in Joint Session 6. Obesity Days 2016, Frankfurt, Deutschland).
83.
84.
Abegg, K., et al., Roux-en-Y gastric bypass surgery reduces bone mineral density and induces metabolic acidosis in rats. Am J Physiol Regul Integr Comp Physiol, 2013. 305(9): p. R999–r1009.CrossRefPubMed
85.
Rubino, F., Medical research: Time to think differently about diabetes. Nature, 2016. 533(7604): p. 459–61.CrossRefPubMed
86.
Bose, M., et al., Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes, 2010. 2(1): p. 47–55.CrossRefPubMed
87.
Isbell, J.M., et al., The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care, 2010. 33(7): p. 1438–42.CrossRefPubMedPubMedCentral
88.
Abdeen, G. and C.W. le Roux, Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review. Obes Surg, 2016. 26(2): p. 410–21.CrossRefPubMed
89.
90.
Abegg, K., et al., Roux-en-Y gastric bypass surgery reduces bone mineral density and induces metabolic acidosis in rats. Am J Physiol Regul Integr Comp Physiol, 2013. 305(9): p. R999–r1009.CrossRefPubMed
91.
Holbrook, T.L. and E. Barrett-Connor, The association of lifetime weight and weight control patterns with bone mineral density in an adult community. Bone Miner, 1993. 20(2): p. 141–9.CrossRefPubMed
92.
Lu, C.W., et al., Fracture Risk After Bariatric Surgery: A 12-Year Nationwide Cohort Study. Medicine (Baltimore), 2015. 94(48): p. e2087.CrossRef
93.
Rosen, C.J. and S. Brown, Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med, 2003. 348(15): p. 1503–4.CrossRefPubMed
94.
Prager, G., Hypoglykämien nach Adipositaschirurgie- Inzidenz, Pathophysiologie und Klinik. 32nd Annual Conference of the German Association for the Study of Obesity (DAG) e.V., 2016(Vortrag in Joint Session 6. Obesity Days 2016, Frankfurt, Deutschland).
95.
Rubino, F., Medical research: Time to think differently about diabetes. Nature, 2016. 533(7604): p. 459–61.CrossRefPubMed
96.
Bose, M., et al., Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes, 2010. 2(1): p. 47–55.CrossRefPubMed
97.
Isbell, J.M., et al., The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care, 2010. 33(7): p. 1438–42.CrossRefPubMedPubMedCentral
Metadaten
Titel
Bariatrische Chirurgie bei Typ-2-Diabetes
Der Magenbypass — eine Chance auf Diabetesremission mit Haken und Ösen
verfasst von
Dr. Gabi Franke-Ullmann
Dr. Marie-Christine Simon
Publikationsdatum
04.09.2017
Verlag
Springer Medizin
Erschienen in
Info Diabetologie / Ausgabe 4/2017
Print ISSN: 1865-5459
Elektronische ISSN: 2196-6362
DOI
https://doi.org/10.1007/s15034-017-0974-9

Weitere Artikel der Ausgabe 4/2017

Info Diabetologie 4/2017 Zur Ausgabe

aktuell

Nur schwache Hinweise auf Schutz vor Atherosklerose durch Metformin

aktuell

PCSK-9-Hemmer auch bei Diabetikern wirksame Lipidsenker

aktuell

Den Diabetes-Risikopatienten auf der Spur

infopharm

Ultraschnelles Insulin mit HbA1c-Vorteil auch nach einem Jahr

journal club

Sechs Monate nur Stillen ist fürs Kindergewicht optimal

journal club

Was Metformin mit dem Mikrobiom macht

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise